Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05908708

Closed-loop Medtronic 780G System in Youth With Type 1 Diabetes

The goal of this observational study is to describe data on Israeli children and youth using the 780G system including data regarding glycemic control parameters, various questionnaires, sleep data, bioimpedance measures, and dietary parameters. The main questions it aims to answer are: • whether the 780G system will improve glycemic control • whether the psychosocial aspects will improve. Participants will be followed once connected to 780G, at baseline, one, three, six months, 1 year, and two years after the connection.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Type 1 Diabetes Autoimmune Diseases Child, Only Diabetes Mellitus Diabetes Mellitus, Type 1 Endocrine System Diseases Glucose Metabolism Disorders Immune System Diseases Metabolic Diseases Nutritional and Metabolic Diseases

Age range

1 year–21 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Patients and Methods:

The study population will include individuals with type 1 diabetes ages 7-18 years who are managed by the pediatric diabetes teams from the AWeSoMe Study Group (five pediatric diabetes multidisciplinary clinics in Israel; Dana-Dwek Children's Hospital, Edmond and Lily Safra Children's Hospital, Maccabi National Juvenile Diabetes Center, Shamir Medical Center and Wolfson Medical Center) and who chose to purchase 780G out-of-pocket as part of their diabetes care, or are eligible according to the updated Israeli basket to receive it. The decision to use 780G will be made prior to and independent of their entrance to the study, and will be based on preferences of the patients and their parents.

Study design:

A prospective multi-center study (AWeSoMe Study Group) of type 1 diabetes patients using the closed-loop Medtronic 780G system as compared to their previous treatment regimen.

Data will be collected at 6 timepoints: baseline (at initiation of 780G system), after 1 month, three months and 6 months, 1 year, and 2 years of the closed-loop Medtronic 780G system usage.

Data collection:

All the data collected are available for healthcare providers (doctors, nurses and dieticians) as part of the routine diabetes clinic visit. The information retrieved from the medical files will include sociodemographic characteristics (current age, sex, socioeconomic position by home address, parent's education level, marital status of parents), anthropometric parameters (height, weight and body mass index), pubertal status, physical activity levels and diabetes-related characteristics. Diabetes-related characteristics: age at diagnosis, autoimmune co-morbidities (thyroid disease and Celiac), glycated hemoglobin (HbA1c) and acute complications (severe hypoglycemic episodes and DKA). Insulin pump and CGM downloaded data retrieved during the 2 weeks prior to the clinic visit: mode of insulin therapy (previous and current), total daily insulin dose (Units/kg/day), total daily carbohydrates (grams/day) and CGM metrics. CGM metrics will include: percent time CGM active, mean glucose level, standard deviation (SD), coefficient of variability (CV), time in range (TIR), time above range (TAR), time below range (TBR) and glucose management indicator (GMI). Closed-loop Medtronic 780G system user evaluation: reason for switching from conventional treatment to closed-loop, automode system exits and patient's/parent's perception of closed-loop system.

In addition to the data mentioned above the following data will be collected:

  • Questionnaires for the:
  • Patients - the quality of life, anxiety, fear of hypoglycemia - child, diabetes management, and nutrition knowledge in diabetes. All of the questionnaires are validated and were translated into Hebrew using the globally-accepted linguistic validation procedure.
  • Parents - the quality of life, fear of hypoglycemia - parent, diabetes management, sleep quality, and nutrition knowledge in diabetes. All of the questionnaires are validated and were translated into Hebrew using the globally-accepted linguistic validation procedure.
  • Bioimpedance parameters
  • Diet - nutrition evaluation through 3-daily diet notes
  • Sleep - sleep evaluation through parents' 3-daily sleep diaries

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of type 1 diabetes Diabetes duration ≥ 6 months Routine attendance at clinic visits Initiation of 780G system usage

Exclusion criteria

Children under the age of 1 year Children without 780G system

Treatment and study plan

Medtronic 780G® hybrid closed loop

Device

Medtronic 780G® hybrid closed loop system uses the commercial "auto-mode" with an insulin pump and continuous glucose monitoring.

Primary outcomes

  1. Time spent in range (70-180 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0,3 months

    Change in time spent in range (70-180 mg/dL) from baseline to three months of closed-loop Medtronic 780G system

  2. Time spent in range (70-180 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0,6 months

    Change in time spent in range (70-180 mg/dL) from baseline to six months of closed-loop Medtronic 780G system

  3. Time spent in range (70-180 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0,12 months

    Change in time spent in range (70-180 mg/dL) from baseline to six months of closed-loop Medtronic 780G system

  4. Time spent in range (70-180 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0,24 months

    Change in time spent in range (70-180 mg/dL) from baseline to six months of closed-loop Medtronic 780G system

Secondary outcomes

  1. HbA1c as assessed from point-of-care clinic visit

    Time frame: 0, 3 months

    Change in HbA1c from baseline to three months of closed-loop Medtronic 780G system

  2. HbA1c as assessed from point-of-care clinic visit

    Time frame: 0, 6 months

    Change in HbA1c from baseline to six months of closed-loop Medtronic 780G system

  3. Time spent below range (≤ 70 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 3 months

    Change in time spent below range (≤ 70 mg/dL) baseline to three months of closed-loop Medtronic 780G system

  4. Time spent below range (≤ 70 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 6 months

    Change in time spent below range (≤ 70 mg/dL and ≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system

  5. Time spent below range (≤ 54 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 3 months

    Change in time spent below range (≤ 54 mg/dL) baseline to three months of closed-loop Medtronic 780G system

  6. Time spent below range (≤ 54 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 6 months

    Change in time spent below range (≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system

  7. Time spent above range (> 180 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 3 months

    Change in time spent above range (> 180 mg/dL) baseline to three months of closed-loop Medtronic 780G system

  8. Time spent above range (> 180 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 6 months

    Change in time spent above range (> 180 mg/dL) baseline to six months of closed-loop Medtronic 780G system

  9. Time spent above range (> 250 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 3 months

    Change in time spent above range (> 250 mg/dL) baseline to three months of closed-loop Medtronic 780G system

  10. Time spent above range (> 250 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 6 months

    Delta time spent above range (> 250 mg/dL) baseline to six months of closed-loop Medtronic 780G system

  11. Quality of life - child as assessed by a questionnaire

    Time frame: 0, 6 months

    Change in quality of life - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 5, max score 100; the higher the score, the better quality of life.

  12. Quality of life - parent as assessed by a questionnaire

    Time frame: 0, 6 months

    Change in quality of life - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 37, max score 185; the higher the score, the better quality of life.

  13. Trait anxiety - child as assessed by a questionnaire

    Time frame: 0, 6 months

    Change in trait anxiety - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 80; the higher the score, the higher the anxiety.

  14. Fear of hypoglycemia - child as assessed by a questionnaire

    Time frame: 0, 6 months

    Change in fear of hypoglycemia - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 25, max score 100; the higher the score, the higher the fear of hypoglycemia.

  15. Fear of hypoglycemia - parent as assessed by a questionnaire

    Time frame: 0, 6 months

    Change in fear of hypoglycemia - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 25, max score 100; the higher the score, the higher the fear of hypoglycemia.

  16. Diabetes management - child as assessed by a questionnaire

    Time frame: 0, 6 months

    Change in diabetes management - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 100; the higher the score, the better the management of diabetes.

  17. Diabetes management - parent as assessed by a questionnaire

    Time frame: 0, 6 months

    Change in diabetes management - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 100; the higher the score, the better the management of diabetes.

  18. Nutrition diaries as assessed by a dietician

    Time frame: 0, 6 months

    Change in carbohydrates grams - baseline to 6 months. Assessment of carbohydrates in grams by a certified pediatric nutritionist.

  19. Sleep quality as assessed by a questionnaire

    Time frame: 0, 6 months

    Change in sleep quality - baseline to 6 months, as assessed by a validated questionnaire, as cited in the Reference section.

  20. HbA1c as assessed from point-of-care clinic visit

    Time frame: 0, 12 months

    Change in HbA1c from baseline to six months of closed-loop Medtronic 780G system

  21. HbA1c as assessed from point-of-care clinic visit

    Time frame: 0, 24 months

    Change in HbA1c from baseline to six months of closed-loop Medtronic 780G system

  22. Time spent below range (≤ 70 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 12 months

    Change in time spent below range (≤ 70 mg/dL and ≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system

  23. Time spent below range (≤ 70 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 24 months

    Change in time spent below range (≤ 70 mg/dL and ≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system

  24. Time spent below range (≤ 54 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 12 months

    Change in time spent below range (≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system

  25. Time spent below range (≤ 54 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 24 months

    Change in time spent below range (≤ 54 mg/dL) baseline to six months of closed-loop Medtronic 780G system

  26. Time spent above range (> 180 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 12 months

    Change in time spent above range (> 180 mg/dL) baseline to six months of closed-loop Medtronic 780G system

  27. Time spent above range (> 180 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 24 months

    Change in time spent above range (> 180 mg/dL) baseline to six months of closed-loop Medtronic 780G system

  28. Time spent above range (> 250 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 12 months

    Delta time spent above range (> 250 mg/dL) baseline to six months of closed-loop Medtronic 780G system

  29. Time spent above range (> 250 mg/dL) as assessed from closed-loop Medtronic 780G system

    Time frame: 0, 24 months

    Delta time spent above range (> 250 mg/dL) baseline to six months of closed-loop Medtronic 780G system

  30. Quality of life - parent as assessed by a questionnaire

    Time frame: 0, 24 months

    Change in quality of life - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 37, max score 185; the higher the score, the better quality of life.

  31. Trait anxiety - child as assessed by a questionnaire

    Time frame: 0, 24 months

    Change in trait anxiety - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 80; the higher the score, the higher the anxiety.

  32. Fear of hypoglycemia - child as assessed by a questionnaire

    Time frame: 0, 24 months

    Change in fear of hypoglycemia - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 25, max score 100; the higher the score, the higher the fear of hypoglycemia.

  33. Fear of hypoglycemia - parent as assessed by a questionnaire

    Time frame: 0, 24 months

    Change in fear of hypoglycemia - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 25, max score 100; the higher the score, the higher the fear of hypoglycemia.

  34. Diabetes management - child as assessed by a questionnaire

    Time frame: 0, 24 months

    Change in diabetes management - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 100; the higher the score, the better the management of diabetes.

  35. Diabetes management - parent as assessed by a questionnaire

    Time frame: 0, 24 months

    Change in diabetes management - baseline to 6 months. A validated questionnaire, as cited in the Reference section. Min score 20, max score 100; the higher the score, the better the management of diabetes.

  36. Nutrition diaries as assessed by a dietician

    Time frame: 0, 24 months

    Change in carbohydrates grams - baseline to 6 months. Assessment of carbohydrates in grams by a certified pediatric nutritionist.

  37. Sleep quality as assessed by a questionnaire

    Time frame: 0, 24 months

    Change in sleep quality - baseline to 6 months, as assessed by a validated questionnaire, as cited in the Reference section.

Study contacts

Contact information is provided by the study sponsor or research team.

Elinor Mauda, BSc

CONTACT

[email protected]

+972543550783

Noah Gruber, MD

CONTACT

[email protected]

+972507181666

Sponsors and collaborators

Lead sponsor

Sheba Medical Center

Other Gov

Collaborators

  • Assaf-Harofeh Medical Center
  • Maccabi Healthcare Services, Israel
  • Tel-Aviv Sourasky Medical Center
  • Wolfson Medical Center

Registry information

Official study title

Title: Closed-loop Medtronic 780G System in Youth With Type 1 Diabetes: AWeSoMe Study Group Prospective Trial

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jun 18, 2023
Registry last updated
Apr 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.